Form 4: Agenus CEO Garo Armen Receives Stock in Lieu of Cash as Part of Compensation

Agenus Inc. CEO Garo H. Armen received 4,169 shares of common stock in lieu of cash as part of his compensation for the pay period ending January 24, 2025.

Summary

• A Form 4 filing reveals that Agenus Inc. CEO Garo H. Armen received 4,169 shares of Agenus common stock on January 24, 2025, as part of his compensation.
• This stock payment was made in lieu of cash salary, with the approval of the Agenus Inc. Compensation Committee.
• The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive and are fully vested upon issuance.
• The price of the stock was $3.57 per share, which was the closing price of Agenus common stock on January 24, 2025.
• Dr. Armen also indirectly owns 133,317 shares through his IRA accounts and 28,950 shares as trustee and general partner.
• He disclaims beneficial ownership to the extent of his pecuniary interest in Pixie Partners.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The CEO taking stock instead of cash could be seen as a positive sign, but it's not definitively bullish.

Positives

• The CEO accepting stock in lieu of cash may signal confidence in the company's future performance.
• The shares are fully vested upon issuance, aligning the CEO's interests with those of the shareholders.

Management Comments

• At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash.

Industry Context

It is not uncommon for executives, especially in biotech companies, to receive stock as part of their compensation packages. This aligns their interests with shareholders and incentivizes them to increase the company's value.

Stakeholder Impact

• Shareholders may view the CEO accepting stock in lieu of cash as a positive sign of confidence in the company's future.

Key Dates